ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma

Wang, Jinghua; Wang, Yanjun; Wan, Li; Chen, Xinyuan; Zhang, Han; Yang, Shuo*; Zhong, Liye*广东省人民医院; 北京大学; 南方医科大学; 武汉大学; 中山大学
Frontiers in Immunology2023-9-18DOI: 10.3389/fimmu.2023.1230017
1被引19阅读
引用收藏
分享

摘要

Background: Lactate, produced through glycolytic metabolism in the tumor microenvironment (TME), is implicated in tumorigenesis and progression in diverse cancers. However, the impact of lactate on the remodeling of the TME in diffuse large B-cell lymphoma (DLBCL) and its implications for therapy options remain unclear.Method: A lactate-related (LAR) scoring model was constructed in DLBCL patients using bioinformatic methods. CIBERSORT, XCELL, and ssGSEA algorithms were used to determine the correlation between LAR score and immune cell infiltration. Tumor Immune Dysfunction and Exclusion (TIDE), rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP) cohorts, and Genomics of Drug Sensitivity in Cancer (GDSC) were utilized to predict the therapeutic response of DLBCL patients. The impact of the hub gene STAT4 on tumor biological behavior and DNA methylation was experimentally validated or accessed by the TSIDE database.Results: The LAR scoring model was developed based on 20 prognosis-related lactate genes, which enabled the division of DLBCL patients into high- and low-risk groups based on the median LAR score. Patients with high-risk DLBCL exhibited significantly worse survival outcomes in both the training cohorts (GSE181063) and the validation cohorts (GSE10846, GSE32918, and GSE69053), as indicated by statistically significant differences (all P<0.05) and area under the curve (AUC) values exceeding 0.6. Immune analyses revealed that low-risk DLBCL patients had higher levels of immune cell infiltration and antitumor immune activation compared to high-risk DLBCL patients. Furthermore, DLBCL patients with high LAR scores were associated with a lower TIDE value and poor therapeutic efficacy of the R-CHOP regimen. GDSC analysis identified 18 drugs that exhibited significant response sensitivity in low-risk DLBCL patients. Moreover, in vitro experiments demonstrated that overexpression of the lactate key gene STAT4 could suppress proliferation and migration, induce cell cycle arrest, and promote cell apoptosis in DLBCL cells. Transcriptional expression and methylation of the STAT4 gene were found to be associated with immunomodulators and chemokines.Conclusion: The lactate-based gene signature effectively predicts the prognosis and regulates TME in DLBCL. Our study underscores the role of lactate gene, STAT4, as an important tumor suppressor in DLBCL. Modulating STAT4 could be a promising strategy for DLBCL in clinical practice.

学科与关键词

关键词
lactatetumor microenvironmentprognosisDNA methylationdiffuse large B-cell lymphoma (DLBCL)
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2023-09-18
卷期
第 14 卷
页码
1230017
DOI
10.3389/fimmu.2023.1230017
语言
ENGLISH
成果收录
SCIE
资助标注
This work was supported by the National Natural Science Foundation of China (No. 82100238), the Science and Technology Program of Guangzhou (No. 202201011046), the High-level Hospital Construction Project of Guangdong Provincial People's Hospital (No. DFJH [82100238]; National Natural Science Foundation of China [202201011046]; Science and Technology Program of Guangzhou [DFJH201923]; High-level Hospital Construction Project of Guangdong Provincial People's Hospital [A2019063]; Medical Scientific Research Foundation of Guangdong Province

作者

  • W

    Wang, Jinghua (第一作者)

    guangdong prov peoples hosp · southern med univ

  • W

    Wang, Yanjun

    sun yat sen univ

查看全部 7 位作者收起作者
  • W

    Wan, Li

    wuhan univ

  • C

    Chen, Xinyuan

    sun yat sen univ

  • Z

    Zhang, Han

    guangdong prov peoples hosp · southern med univ

  • Y

    Yang, Shuo (通讯)

    peking univ shenzhen

  • Z

    Zhong, Liye (通讯)

    guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417